美托洛尔治疗慢性充血性心力衰竭的临床观察

Treatment to clinical research of congestive heart failure with betaloc

目的 :观察美托洛尔治疗充血性心力衰竭病人的疗效。方法 :选择 98例NYHA心功能Ⅱ～Ⅲ级病人分治疗组 5 0例与对照组 4 8例。治疗组加服 6 .2 5mg/d ,以后根据耐受情况逐渐加大用量 ,总量控制在 5 0mg～ 10 0mg/d。服药前与服药后每 2个月进行一次胸片及超声心动图检查 ,每半月检查一次心电图。观察 2组患者心率、心率失常发生率心胸比值及左室射血分数 (LVEF) ,NYHA心功能分级。结果 :治疗组在第六个月后左心室射血分数增加 ,心胸比值小 ,二者都高于对照组 (P <0 .0 1) ,心率、心律失常发生率和NYNA心功能分明显低于对照组 (P <0 .0 1)。结论 :美托洛尔治疗充血性心力衰竭病人能增加左室射血分数 ,改善心功能 ,同时也能降低心律失常发生率 ,是治疗充血性心力衰竭的理想药物。

Objective: Treatment to clinical research of congestive heart failure with Betaloc. Methods: Take examples of 98 patients as heart functionⅡ～Ⅲ(NYHY) as random sampling as treatment group(50 patients) and control group(48 patients). Increasing the dosage on the base of patients endurance. Treated group given doubled dosage, first dosage is 6.25mg/D, the whole dosage is controlled as 50mg/d,Before or after taking medicine, every 2 months, the patients should. have a chest X-rayed, two dimensional enclocardiography. Half month the patients should have an electrocaodiogram, observing his heart rate and the Cardiac arrhythmias and The heart and thorax ratio and left ventricular ejection fraction. Results:After taking Betaloc of six months, treated group left ventricular ejection fraction increases. The heart and thorax ratio decrease; both are higher than control group(p<0.05).Cardiac arrhythmias is obviously lower than control group(p<0.01).Conclusions: Treatment to clinical research of congestive heart failure with Betaloc can increase left ventricular ejection fraction, improving faction of heart. At the same time, it can reduce the rate of cardiac arrhythmias, it is an ideal medicine to treat CHF patients.